Kardigan surges 31% in strong biotech IPO debut

Kardigan’s first day on Nasdaq read like a test of whether investors still want to take biotech risk, and the answer came back emphatically yes. The heart-drug developer opened at $16.25, above its $16 IPO price, and finished its debut at $22, up 37.5% for the day after briefly trading more than 22% above the offer price during the session.

The surge mattered beyond one stock. In a market that has been choppy for new listings, Kardigan’s reception suggested the biotech IPO window is open again, at least for companies with advanced clinical programs and near-term catalysts. The company raised $400 million by selling 25 million shares in an upsized offering, giving it fresh capital as it prepares to report data from its pipeline in the first half of 2027.

Kardigan priced the shares after filing its S-1 with the U.S. Securities and Exchange Commission on May 26, 2026, and after the registration statement became effective on June 17. J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC served as underwriters, and they have a 30-day option to buy up to 3.75 million additional shares. The stock began trading on June 18 under the ticker KARD, and the offering is expected to close on June 22, subject to customary conditions.

Investors were not buying a blank check. Kardigan has told investors it will not have enough cash to fund operations for at least 12 months, a reality that helps explain why it moved to tap the market now. But the company also arrives with a pedigree that is unusually easy for public investors to judge: Chief executive Tassos Gianakakos and chief medical officer Jay Edelberg previously helped develop mavacamten at MyoKardia, the company Bristol Myers Squibb bought in 2020 for about $13.1 billion, or $225 a share, and completed on November 17, 2020.

That history matters because Kardigan is trying to turn a scientific track record into a public-market story. The company says it is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, and it is pursuing three late-stage experimental treatments: danicamtiv, ataciguat and tonlamarsen. Its lead program, danicamtiv, is an oral cardiac myosin activator in a Phase 2b/3 trial for genetic dilated cardiomyopathy caused by MYH7 and TTN variants, with topline data expected in the first half of 2027.

BioPharma Dive said Kardigan’s debut helped extend a 2026 biotech IPO streak, with four biotechs raising at least $400 million in IPO proceeds this year, the most in a single year since 2021. That does not prove the financing market has fully normalized, but it does suggest investors are again willing to back companies with credible development plans, clear milestones and a story strong enough to overcome a hesitant market. For Kardigan, the bigger question is whether this was the start of a broader reopening or a one-off driven by a particularly convincing cardiovascular pipeline.